Clinical trial · Observational
Coronavirus Infection (COVID-19) and Radical Surgery in Patients With Early-stage Lung Cancer
Effects of Coronavirus Infection (COVID-19) on the Timing and Prognosis of Radical Surgery in Patients With Early-stage Lung Cancer
NCT05684549CI-TRIAL-00078320COVIDLungSurgunknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The goal of this observational study is to learn about the effects of coronavirus infection in patients with early-stage lung cancer. The main question it aims to answer is whether the interval of surgery and COVID-19 infection will affect the surgery and prognosis of the patients.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Corona Virus Infection | — | UNRESOLVED | — |
| Surgery | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| No intervention | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- stage I/II lung cancer patients
- description
- Patients with stage I/II lung cancer will receive radical surgery.
- interventionNames
- Other: No intervention
Primary outcomes (1)
- measure
- postoperative morbidity
- timeFrame
- postoperative in-hospital stay up to 30 days
- description
- rate of perioperative complications, mainly include: pneumonia, respiratory failure, pulmonary embolism, arrhythmia, sepsis, cerebrovascular accident, myocardial injury, acute kidney injury.
Secondary outcomes (6)
- measure
- postoperative hospital stay
- timeFrame
- postoperative in-hospital stay up to 30 days
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Clinically diagnosed stage I and stage II lung cancer, who are about to receive wedge resection, segmental resection, sleeve resection, lobectomy, or pneumonectomy under general anaesthesia. * Volunteer to participate in the study with good compliance. Able to complete the observation and follow-up and have signed the informed consent. * ASA score: I-III; * Cardiopulmonary functions meet the requirements of radical operation for lung cancer with normal liver and kidney functions. Exclusion Criteria: * Neurologic, mental illness or mental disorder which is hard to control, poor compliance, unable to cooperate or describe the treatment response; * Clinically diagnosed stage III and stage IV lung cancer or patients who received neoadjuvant treatment before surgery; * Patients developed symptoms alike coronavirus infection but are not confirmed by viral RNA detection by quantitative RT-PCR or antigen testing kits. * Serious heart, lung, liver and kidney dysfunction and unable to tolerate the operation
References
Publications (1)
- DERIVEDNiu Z, Zhu F, Cao Y, Luo C, Liu D, Wang C, Qiu Z, Peng L, Du M, Jin R, Yan Y, Dong D, Jing H, Wang X, Guo W, Guo Z, Li C, Han D, Zhang Y, Xiang J, Du H, Chen K, Yin Z, Yang J, Zhong W, Zhou Y, Wang M, Ma D, Li H. Impact of coronavirus disease 2019 on surgery in patients with early-stage lung cancer: the COVIDLungSurg prospective cohort study. Transl Lung Cancer Res. 2025 May 30;14(5):1677-1687. doi: 10.21037/tlcr-2024-1276. Epub 2025 May 28. PMID 40535078